| ■ 영문 제목 : Global Central Nervous System (CNS) Stimulant Drugs Market 2023-2027 | |
![]() | ■ 상품코드 : IRTNTR72695-23 ■ 조사/발행회사 : Technavio ■ 발행일 : 2023년 2월 최신판(2025년 또는 2026년)은 문의주세요. ■ 페이지수 : 약120 ■ 작성언어 : 영문 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 (24시간 이내) ■ 조사대상 지역 : 북미, 유럽, 아시아 태평양, 기타 지역 ■ 산업 분야 : 의료 |
| Single User (1명 열람용) | USD2,500 ⇒환산₩3,500,000 | 견적의뢰/주문/질문 |
| Enterprise License (동일기업내 공유가능) | USD4,000 ⇒환산₩5,600,000 | 견적의뢰/주문/질문 |
|
※가격옵션 설명 - 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다. - 지불방법은 계좌이체/무통장입금 또는 카드결제입니다. |
| Technavio사의 본 연구 보고서에 따르면 세계의 중추 신경계 (CNS) 자극제 시장 규모가 2022 년과 2027 년 사이에 6,486.71 백만 달러에 이르며, 예측 기간 동안 연평균 5.8 % 성장할 것으로 전망하고 있습니다. 본 조사 보고서는 세계의 중추 신경계 (CNS) 자극제 시장에 대해 조사 및 분석하여, 개요, 시장 현황, 시장 규모 예측, 과거 시장 규모, Five Force 분석, 유통 채널별 (병원, 기타) 분석, 용도별 (주의 결함 및 다동성 장애, 기면증, 기타) 분석, 고객 현황, 지역별 현황 (북미, 아시아 태평양, 유럽, 기타 지역, 미국, 캐나다, 영국, 독일, 중국) 분석, 성장 요인/과제/동향, 기업 현황, 기업 분석 등의 내용을 게재하고 있습니다. 또한 본 자료는 Astellas Pharma Inc., Azurity Pharmaceuticals Inc., Elite Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., Ironshore, Jazz Pharmaceuticals Plc, KemPharm Inc., Merck and Co. Inc., Novartis AG, Pfizer 등의 기업 정보가 포함되어 있습니다. ・개요 ・시장 현황 ・시장 규모 예측 ・과거 시장 규모 ・Five Force 분석 ・세계의 중추 신경계 (CNS) 자극제 시장 규모 : 유통 채널별 - 병원 채널의 시장 규모 - 기타 채널의 시장 규모 ・세계의 중추 신경계 (CNS) 자극제 시장 규모 : 용도별 - 주의 결함 및 다동성 장애에 사용되는 중추 신경계 (CNS) 자극제의 시장 규모 - 기면증에 사용되는 중추 신경계 (CNS) 자극제의 시장 규모 - 기타 용도에 사용되는 중추 신경계 (CNS) 자극제의 시장 규모 ・고객 현황 ・지역별 현황 - 북미의 중추신경계 (CNS) 자극제 시장 규모 - 유럽의 중추신경계 (CNS) 자극제 시장 규모 - 아시아 태평양의 중추신경계 (CNS) 자극제 시장 규모 - 기타 지역의 중추신경계 (CNS) 자극제 시장 규모 - 미국의 중추신경계 (CNS) 자극제 시장 규모 - 캐나다의 중추신경계 (CNS) 자극제 시장 규모 - 영국의 중추신경계 (CNS) 자극제 시장 규모 - 독일의 중추신경계 (CNS) 자극제 시장 규모 - 중국의 중추신경계 (CNS) 자극제 시장 규모 ・성장 요인/과제/동향 ・기업 현황 ・기업 분석 Technavio 사는 이익, 가격, 경쟁, 프로모션과 같은 주요 매개 변수를 분석하여, 다수의 소스로부터 데이터를 조사, 통합 및 합산하여 중추신경계 (CNS) 자극제 시장에 대한 상세하고 종합적인 결과를 제공합니다. 또한, 주요 산업의 영향 요인을 분석하여 시장의 다양한 관점을 제시합니다. 제시된 데이터는 포괄적이고 신뢰할 수 있으며, 1차 및 2차에 걸친 광범위한 조사 결과입니다. 덧붙여 Technavio 사의 시장 조사 보고서는 정확한 중추신경계 (CNS) 자극제 시장 성장을 예측하기 위해, 정성적 및 정량적 조사를 사용하여, 명확한 경쟁 현황과 상세한 벤더 선택 방법 및 분석을 제공합니다. |
글로벌 중추신경계(CNS) 자극제 약물 시장에 대한 Technavio의 보고서에 따르면, 이 시장은 2022년부터 2027년까지 약 6486.71억 달러 성장할 것으로 예상되며, 이 기간 동안 연평균 성장률(CAGR)은 5.8%에 이를 것으로 보인다. 보고서는 현재 시장 상황, 최신 트렌드 및 성장 요인, 도전 과제, 그리고 약 25개 공급업체에 대한 분석을 포함하여 중추신경계 자극제 약물 시장에 대한 포괄적인 분석을 제공한다.
시장 성장의 주요 요인은 CNS 장애의 증가, 새로운 자극제의 승인, 그리고 전 세계적으로 자극제 사용의 증가로 요약될 수 있다. 또한, 새로운 세대의 약물에 대한 수요 증가가 향후 몇 년 동안 CNS 자극제 약물 시장 성장의 주요 원인으로 지목되고 있으며, 전 세계적으로 대마초 합법화에 대한 수요 증가와 약물 재사용의 증가는 시장 수요에 긍정적인 영향을 미칠 것으로 예상된다.
Technavio의 중추신경계 자극제 약물 시장은 유통 채널, 용도, 지역별로 세분화되어 있다. 유통 채널은 병원과 기타로 나뉘며, 용도는 주의력 결핍 과다 행동 장애(ADHD), 기면증, 기타로 구분된다. 지역별로는 북미, 유럽, 아시아, 기타 지역(ROW)으로 나뉜다.
이 보고서는 시장 규모, 예측, 산업 분석 등 다양한 분야를 다루고 있으며, 고객이 시장에서의 위치를 개선할 수 있도록 지원하기 위해 주요 공급업체에 대한 상세한 분석을 제공한다. 주요 공급업체로는 Astellas Pharma Inc., Azurity Pharmaceuticals Inc., Elite Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., Ironshore, Jazz Pharmaceuticals Plc, KemPharm Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., Purdue Pharma LP, Sanofi SA, Shionogi and Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Tris Pharma Inc., Viatris Inc., Thermo Fisher Scientific Inc. 등이 있다. 보고서는 또한 시장 성장에 영향을 미칠 예정인 향후 트렌드와 도전 과제에 대한 정보를 포함하고 있어 기업들이 향후 성장 기회를 전략적으로 활용할 수 있도록 돕는다.
이 연구는 산업 내 주요 참여자들로부터의 1차 및 2차 정보의 객관적인 조합을 사용하여 수행되었으며, 포괄적인 시장 및 공급업체 환경과 주요 공급업체에 대한 분석을 포함하고 있다. Technavio는 수익, 가격, 경쟁 및 프로모션과 같은 주요 매개변수에 대한 분석을 통해 시장을 자세히 설명하며, 주요 산업 영향력을 식별하여 다양한 시장 측면을 제시한다. 제공되는 데이터는 포괄적이고 신뢰할 수 있으며, 광범위한 연구의 결과로 얻어진 것이다.
■ 보고서 목차• 1 요약 • 3 시장 규모 o 표 34: 병원 – 시장 규모 및 전망 차트(2022-2027년, 백만 달러) o 표 38: 기타 부문 차트 – 시장 규모 및 전망 2022-2027 (백만 달러) o 표 52: 기면증 차트 – 2022-2027년 시장 규모 및 전망 (백만 달러) o 표 67: 북미 – 시장 규모 및 전망 2022-2027년 차트(백만 달러) o 표 70: 데이터 표 북미 – 2022-2027년 전년 대비 성장률(%) o 표 79: 기타 지역 (ROW) 시장 차트 – 2022-2027년 (백만 달러) o 표 82: 기타 지역 (ROW) 시장 데이터 표 – 전년 대비 성장률 2022-2027 (%) • 12. 벤더 분석 o 표 128: 켐팜 – 개요 o 표 156: 테바 제약 주식회사 – 개요 o 표 161: 트리스 파마 주식회사 – 개요 첨부 자료: 표 1: 요약 – 시장 개요 차트 첨부자료 37: 병원 시장 전년 대비 성장률 데이터표 2022-2027년 (%) 첨부자료74: 유럽 데이터 표 – 전년 대비 성장률 2022-2027년 (%) 표 82: 기타 국가(ROW) 데이터 표 – 2022-2027년 전년 대비 성장률(%) 표 98: 독일 데이터 표 – 2022-2027년 전년 대비 성장률(%) 첨부자료 120: 히사미츠 제약(Hisamitsu Pharmaceutical Co. Inc.) – 주요 제공 서비스 첨부자료 146: 퍼듀파마(Purdue Pharma LP) – 주요 제품 및 서비스 첨부자료 162: 트리스 파마(Tris Pharma Inc.) – 제품/서비스 o 1.1 Market overview o Exhibit 01: Executive Summary - Chart on Market Overview o Exhibit 02: Executive Summary - Data Table on Market Overview o Exhibit 03: Executive Summary - Chart on Global Market Characteristics o Exhibit 04: Executive Summary - Chart on Market by Geography o Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel o Exhibit 06: Executive Summary - Chart on Market Segmentation by Application o Exhibit 07: Executive Summary - Chart on Incremental Growth o Exhibit 08: Executive Summary - Data Table on Incremental Growth o Exhibit 09: Executive Summary - Chart on Vendor Market Positioning • 2 Market Landscape o 2.1 Market ecosystem o Exhibit 10: Parent market o Exhibit 11: Market Characteristics • 3 Market Sizing o 3.1 Market definition o Exhibit 12: Offerings of vendors included in the market definition o 3.2 Market segment analysis o Exhibit 13: Market segments o 3.3 Market size 2022 o 3.4 Market outlook: Forecast for 2022-2027 o Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million) o Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million) o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%) o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) • 4 Historic Market Size o 4.1 Global central nervous system (CNS) stimulant drugs market 2017 - 2021 o Exhibit 18: Historic Market Size - Data Table on Global central nervous system (CNS) stimulant drugs market 2017 - 2021 ($ million) o 4.2 Distribution channel Segment Analysis 2017 - 2021 o Exhibit 19: Historic Market Size - Distribution channel Segment 2017 - 2021 ($ million) o 4.3 Application Segment Analysis 2017 - 2021 o Exhibit 20: Historic Market Size - Application Segment 2017 - 2021 ($ million) o 4.4 Geography Segment Analysis 2017 - 2021 o Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million) o 4.5 Country Segment Analysis 2017 - 2021 o Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million) • 5 Five Forces Analysis o 5.1 Five forces summary o Exhibit 23: Five forces analysis - Comparison between 2022 and 2027 o 5.2 Bargaining power of buyers o Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027 o 5.3 Bargaining power of suppliers o Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027 o 5.4 Threat of new entrants o Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027 o 5.5 Threat of substitutes o Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027 o 5.6 Threat of rivalry o Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027 o 5.7 Market condition o Exhibit 29: Chart on Market condition - Five forces 2022 and 2027 • 6 Market Segmentation by Distribution Channel o 6.1 Market segments o Exhibit 30: Chart on Distribution Channel - Market share 2022-2027 (%) o Exhibit 31: Data Table on Distribution Channel - Market share 2022-2027 (%) o 6.2 Comparison by Distribution Channel o Exhibit 32: Chart on Comparison by Distribution Channel o Exhibit 33: Data Table on Comparison by Distribution Channel o 6.3 Hospitals - Market size and forecast 2022-2027 o Exhibit 34: Chart on Hospitals - Market size and forecast 2022-2027 ($ million) o Exhibit 35: Data Table on Hospitals - Market size and forecast 2022-2027 ($ million) o Exhibit 36: Chart on Hospitals - Year-over-year growth 2022-2027 (%) o Exhibit 37: Data Table on Hospitals - Year-over-year growth 2022-2027 (%) o 6.4 Others - Market size and forecast 2022-2027 o Exhibit 38: Chart on Others - Market size and forecast 2022-2027 ($ million) o Exhibit 39: Data Table on Others - Market size and forecast 2022-2027 ($ million) o Exhibit 40: Chart on Others - Year-over-year growth 2022-2027 (%) o Exhibit 41: Data Table on Others - Year-over-year growth 2022-2027 (%) o 6.5 Market opportunity by Distribution Channel o Exhibit 42: Market opportunity by Distribution Channel ($ million) o Exhibit 43: Data Table on Market opportunity by Distribution Channel ($ million) • 7 Market Segmentation by Application o 7.1 Market segments o Exhibit 44: Chart on Application - Market share 2022-2027 (%) o Exhibit 45: Data Table on Application - Market share 2022-2027 (%) o 7.2 Comparison by Application o Exhibit 46: Chart on Comparison by Application o Exhibit 47: Data Table on Comparison by Application o 7.3 Attention-deficit hyperactivity disorder - Market size and forecast 2022-2027 o Exhibit 48: Chart on Attention-deficit hyperactivity disorder - Market size and forecast 2022-2027 ($ million) o Exhibit 49: Data Table on Attention-deficit hyperactivity disorder - Market size and forecast 2022-2027 ($ million) o Exhibit 50: Chart on Attention-deficit hyperactivity disorder - Year-over-year growth 2022-2027 (%) o Exhibit 51: Data Table on Attention-deficit hyperactivity disorder - Year-over-year growth 2022-2027 (%) o 7.4 Narcolepsy - Market size and forecast 2022-2027 o Exhibit 52: Chart on Narcolepsy - Market size and forecast 2022-2027 ($ million) o Exhibit 53: Data Table on Narcolepsy - Market size and forecast 2022-2027 ($ million) o Exhibit 54: Chart on Narcolepsy - Year-over-year growth 2022-2027 (%) o Exhibit 55: Data Table on Narcolepsy - Year-over-year growth 2022-2027 (%) o 7.5 Others - Market size and forecast 2022-2027 o Exhibit 56: Chart on Others - Market size and forecast 2022-2027 ($ million) o Exhibit 57: Data Table on Others - Market size and forecast 2022-2027 ($ million) o Exhibit 58: Chart on Others - Year-over-year growth 2022-2027 (%) o Exhibit 59: Data Table on Others - Year-over-year growth 2022-2027 (%) o 7.6 Market opportunity by Application o Exhibit 60: Market opportunity by Application ($ million) o Exhibit 61: Data Table on Market opportunity by Application ($ million) • 8 Customer Landscape o 8.1 Customer landscape overview o Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria • 9 Geographic Landscape o 9.1 Geographic segmentation o Exhibit 63: Chart on Market share by geography 2022-2027 (%) o Exhibit 64: Data Table on Market share by geography 2022-2027 (%) o 9.2 Geographic comparison o Exhibit 65: Chart on Geographic comparison o Exhibit 66: Data Table on Geographic comparison o 9.3 North America - Market size and forecast 2022-2027 o Exhibit 67: Chart on North America - Market size and forecast 2022-2027 ($ million) o Exhibit 68: Data Table on North America - Market size and forecast 2022-2027 ($ million) o Exhibit 69: Chart on North America - Year-over-year growth 2022-2027 (%) o Exhibit 70: Data Table on North America - Year-over-year growth 2022-2027 (%) o 9.4 Europe - Market size and forecast 2022-2027 o Exhibit 71: Chart on Europe - Market size and forecast 2022-2027 ($ million) o Exhibit 72: Data Table on Europe - Market size and forecast 2022-2027 ($ million) o Exhibit 73: Chart on Europe - Year-over-year growth 2022-2027 (%) o Exhibit 74: Data Table on Europe - Year-over-year growth 2022-2027 (%) o 9.5 Asia - Market size and forecast 2022-2027 o Exhibit 75: Chart on Asia - Market size and forecast 2022-2027 ($ million) o Exhibit 76: Data Table on Asia - Market size and forecast 2022-2027 ($ million) o Exhibit 77: Chart on Asia - Year-over-year growth 2022-2027 (%) o Exhibit 78: Data Table on Asia - Year-over-year growth 2022-2027 (%) o 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 o Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) o Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) o Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) o Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) o 9.7 US - Market size and forecast 2022-2027 o Exhibit 83: Chart on US - Market size and forecast 2022-2027 ($ million) o Exhibit 84: Data Table on US - Market size and forecast 2022-2027 ($ million) o Exhibit 85: Chart on US - Year-over-year growth 2022-2027 (%) o Exhibit 86: Data Table on US - Year-over-year growth 2022-2027 (%) o 9.8 Canada - Market size and forecast 2022-2027 o Exhibit 87: Chart on Canada - Market size and forecast 2022-2027 ($ million) o Exhibit 88: Data Table on Canada - Market size and forecast 2022-2027 ($ million) o Exhibit 89: Chart on Canada - Year-over-year growth 2022-2027 (%) o Exhibit 90: Data Table on Canada - Year-over-year growth 2022-2027 (%) o 9.9 UK - Market size and forecast 2022-2027 o Exhibit 91: Chart on UK - Market size and forecast 2022-2027 ($ million) o Exhibit 92: Data Table on UK - Market size and forecast 2022-2027 ($ million) o Exhibit 93: Chart on UK - Year-over-year growth 2022-2027 (%) o Exhibit 94: Data Table on UK - Year-over-year growth 2022-2027 (%) o 9.10 Germany - Market size and forecast 2022-2027 o Exhibit 95: Chart on Germany - Market size and forecast 2022-2027 ($ million) o Exhibit 96: Data Table on Germany - Market size and forecast 2022-2027 ($ million) o Exhibit 97: Chart on Germany - Year-over-year growth 2022-2027 (%) o Exhibit 98: Data Table on Germany - Year-over-year growth 2022-2027 (%) o 9.11 China - Market size and forecast 2022-2027 o Exhibit 99: Chart on China - Market size and forecast 2022-2027 ($ million) o Exhibit 100: Data Table on China - Market size and forecast 2022-2027 ($ million) o Exhibit 101: Chart on China - Year-over-year growth 2022-2027 (%) o Exhibit 102: Data Table on China - Year-over-year growth 2022-2027 (%) o 9.12 Market opportunity by geography o Exhibit 103: Market opportunity by geography ($ million) o Exhibit 104: Data Tables on Market opportunity by geography ($ million) • 10 Drivers, Challenges, and Trends o 10.1 Market drivers o 10.2 Market challenges o 10.3 Impact of drivers and challenges o Exhibit 105: Impact of drivers and challenges in 2022 and 2027 o 10.4 Market trends • 11 Vendor Landscape o 11.1 Overview o 11.2 Vendor landscape o Exhibit 106: Overview on Criticality of inputs and Factors of differentiation o 11.3 Landscape disruption o Exhibit 107: Overview on factors of disruption o 11.4 Industry risks o Exhibit 108: Impact of key risks on business • 12 Vendor Analysis o 12.1 Vendors covered o Exhibit 109: Vendors covered o 12.2 Market positioning of vendors o Exhibit 110: Matrix on vendor position and classification o 12.3 Azurity Pharmaceuticals Inc. o Exhibit 111: Azurity Pharmaceuticals Inc. - Overview o Exhibit 112: Azurity Pharmaceuticals Inc. - Product / Service o Exhibit 113: Azurity Pharmaceuticals Inc. - Key offerings o 12.4 Elite Pharmaceuticals Inc. o Exhibit 114: Elite Pharmaceuticals Inc. - Overview o Exhibit 115: Elite Pharmaceuticals Inc. - Business segments o Exhibit 116: Elite Pharmaceuticals Inc. - Key offerings o Exhibit 117: Elite Pharmaceuticals Inc. - Segment focus o 12.5 Hisamitsu Pharmaceutical Co. Inc. o Exhibit 118: Hisamitsu Pharmaceutical Co. Inc. - Overview o Exhibit 119: Hisamitsu Pharmaceutical Co. Inc. - Product / Service o Exhibit 120: Hisamitsu Pharmaceutical Co. Inc. - Key offerings o 12.6 Ironshore o Exhibit 121: Ironshore - Overview o Exhibit 122: Ironshore - Product / Service o Exhibit 123: Ironshore - Key offerings o 12.7 Jazz Pharmaceuticals Plc o Exhibit 124: Jazz Pharmaceuticals Plc - Overview o Exhibit 125: Jazz Pharmaceuticals Plc - Product / Service o Exhibit 126: Jazz Pharmaceuticals Plc - Key news o Exhibit 127: Jazz Pharmaceuticals Plc - Key offerings o 12.8 KemPharm Inc. o Exhibit 128: KemPharm Inc. - Overview o Exhibit 129: KemPharm Inc. - Product / Service o Exhibit 130: KemPharm Inc. - Key offerings o 12.9 Merck and Co. Inc. o Exhibit 131: Merck and Co. Inc. - Overview o Exhibit 132: Merck and Co. Inc. - Business segments o Exhibit 133: Merck and Co. Inc. - Key news o Exhibit 134: Merck and Co. Inc. - Key offerings o Exhibit 135: Merck and Co. Inc. - Segment focus o 12.10 Novartis AG o Exhibit 136: Novartis AG - Overview o Exhibit 137: Novartis AG - Business segments o Exhibit 138: Novartis AG - Key offerings o Exhibit 139: Novartis AG - Segment focus o 12.11 Pfizer Inc. o Exhibit 140: Pfizer Inc. - Overview o Exhibit 141: Pfizer Inc. - Product / Service o Exhibit 142: Pfizer Inc. - Key news o Exhibit 143: Pfizer Inc. - Key offerings o 12.12 Purdue Pharma LP o Exhibit 144: Purdue Pharma LP - Overview o Exhibit 145: Purdue Pharma LP - Product / Service o Exhibit 146: Purdue Pharma LP - Key offerings o 12.13 Sanofi SA o Exhibit 147: Sanofi SA - Overview o Exhibit 148: Sanofi SA - Business segments o Exhibit 149: Sanofi SA - Key news o Exhibit 150: Sanofi SA - Key offerings o Exhibit 151: Sanofi SA - Segment focus o 12.14 Takeda Pharmaceutical Co. Ltd. o Exhibit 152: Takeda Pharmaceutical Co. Ltd. - Overview o Exhibit 153: Takeda Pharmaceutical Co. Ltd. - Product / Service o Exhibit 154: Takeda Pharmaceutical Co. Ltd. - Key news o Exhibit 155: Takeda Pharmaceutical Co. Ltd. - Key offerings o 12.15 Teva Pharmaceutical Industries Ltd. o Exhibit 156: Teva Pharmaceutical Industries Ltd. - Overview o Exhibit 157: Teva Pharmaceutical Industries Ltd. - Business segments o Exhibit 158: Teva Pharmaceutical Industries Ltd. - Key news o Exhibit 159: Teva Pharmaceutical Industries Ltd. - Key offerings o Exhibit 160: Teva Pharmaceutical Industries Ltd. - Segment focus o 12.16 Tris Pharma Inc. o Exhibit 161: Tris Pharma Inc. - Overview o Exhibit 162: Tris Pharma Inc. - Product / Service o Exhibit 163: Tris Pharma Inc. - Key offerings o 12.17 Viatris Inc. o Exhibit 164: Viatris Inc. - Overview o Exhibit 165: Viatris Inc. - Business segments o Exhibit 166: Viatris Inc. - Key offerings o Exhibit 167: Viatris Inc. - Segment focus • 13 Appendix o 13.1 Scope of the report o 13.2 Inclusions and exclusions checklist o Exhibit 168: Inclusions checklist o Exhibit 169: Exclusions checklist o 13.3 Currency conversion rates for US$ o Exhibit 170: Currency conversion rates for US$ o 13.4 Research methodology o Exhibit 171: Research methodology o Exhibit 172: Validation techniques employed for market sizing o Exhibit 173: Information sources o 13.5 List of abbreviations o Exhibit 174: List of abbreviations Exhibits: Exhibits1: Executive Summary - Chart on Market Overview Exhibits2: Executive Summary - Data Table on Market Overview Exhibits3: Executive Summary - Chart on Global Market Characteristics Exhibits4: Executive Summary - Chart on Market by Geography Exhibits5: Executive Summary - Chart on Market Segmentation by Distribution Channel Exhibits6: Executive Summary - Chart on Market Segmentation by Application Exhibits7: Executive Summary - Chart on Incremental Growth Exhibits8: Executive Summary - Data Table on Incremental Growth Exhibits9: Executive Summary - Chart on Vendor Market Positioning Exhibits10: Parent market Exhibits11: Market Characteristics Exhibits12: Offerings of vendors included in the market definition Exhibits13: Market segments Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million) Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million) Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%) Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) Exhibits18: Historic Market Size - Data Table on Global central nervous system (CNS) stimulant drugs market 2017 - 2021 ($ million) Exhibits19: Historic Market Size - Distribution channel Segment 2017 - 2021 ($ million) Exhibits20: Historic Market Size - Application Segment 2017 - 2021 ($ million) Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million) Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million) Exhibits23: Five forces analysis - Comparison between 2022 and 2027 Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027 Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027 Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027 Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027 Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027 Exhibits29: Chart on Market condition - Five forces 2022 and 2027 Exhibits30: Chart on Distribution Channel - Market share 2022-2027 (%) Exhibits31: Data Table on Distribution Channel - Market share 2022-2027 (%) Exhibits32: Chart on Comparison by Distribution Channel Exhibits33: Data Table on Comparison by Distribution Channel Exhibits34: Chart on Hospitals - Market size and forecast 2022-2027 ($ million) Exhibits35: Data Table on Hospitals - Market size and forecast 2022-2027 ($ million) Exhibits36: Chart on Hospitals - Year-over-year growth 2022-2027 (%) Exhibits37: Data Table on Hospitals - Year-over-year growth 2022-2027 (%) Exhibits38: Chart on Others - Market size and forecast 2022-2027 ($ million) Exhibits39: Data Table on Others - Market size and forecast 2022-2027 ($ million) Exhibits40: Chart on Others - Year-over-year growth 2022-2027 (%) Exhibits41: Data Table on Others - Year-over-year growth 2022-2027 (%) Exhibits42: Market opportunity by Distribution Channel ($ million) Exhibits43: Data Table on Market opportunity by Distribution Channel ($ million) Exhibits44: Chart on Application - Market share 2022-2027 (%) Exhibits45: Data Table on Application - Market share 2022-2027 (%) Exhibits46: Chart on Comparison by Application Exhibits47: Data Table on Comparison by Application Exhibits48: Chart on Attention-deficit hyperactivity disorder - Market size and forecast 2022-2027 ($ million) Exhibits49: Data Table on Attention-deficit hyperactivity disorder - Market size and forecast 2022-2027 ($ million) Exhibits50: Chart on Attention-deficit hyperactivity disorder - Year-over-year growth 2022-2027 (%) Exhibits51: Data Table on Attention-deficit hyperactivity disorder - Year-over-year growth 2022-2027 (%) Exhibits52: Chart on Narcolepsy - Market size and forecast 2022-2027 ($ million) Exhibits53: Data Table on Narcolepsy - Market size and forecast 2022-2027 ($ million) Exhibits54: Chart on Narcolepsy - Year-over-year growth 2022-2027 (%) Exhibits55: Data Table on Narcolepsy - Year-over-year growth 2022-2027 (%) Exhibits56: Chart on Others - Market size and forecast 2022-2027 ($ million) Exhibits57: Data Table on Others - Market size and forecast 2022-2027 ($ million) Exhibits58: Chart on Others - Year-over-year growth 2022-2027 (%) Exhibits59: Data Table on Others - Year-over-year growth 2022-2027 (%) Exhibits60: Market opportunity by Application ($ million) Exhibits61: Data Table on Market opportunity by Application ($ million) Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria Exhibits63: Chart on Market share by geography 2022-2027 (%) Exhibits64: Data Table on Market share by geography 2022-2027 (%) Exhibits65: Chart on Geographic comparison Exhibits66: Data Table on Geographic comparison Exhibits67: Chart on North America - Market size and forecast 2022-2027 ($ million) Exhibits68: Data Table on North America - Market size and forecast 2022-2027 ($ million) Exhibits69: Chart on North America - Year-over-year growth 2022-2027 (%) Exhibits70: Data Table on North America - Year-over-year growth 2022-2027 (%) Exhibits71: Chart on Europe - Market size and forecast 2022-2027 ($ million) Exhibits72: Data Table on Europe - Market size and forecast 2022-2027 ($ million) Exhibits73: Chart on Europe - Year-over-year growth 2022-2027 (%) Exhibits74: Data Table on Europe - Year-over-year growth 2022-2027 (%) Exhibits75: Chart on Asia - Market size and forecast 2022-2027 ($ million) Exhibits76: Data Table on Asia - Market size and forecast 2022-2027 ($ million) Exhibits77: Chart on Asia - Year-over-year growth 2022-2027 (%) Exhibits78: Data Table on Asia - Year-over-year growth 2022-2027 (%) Exhibits79: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibits80: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibits81: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibits82: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibits83: Chart on US - Market size and forecast 2022-2027 ($ million) Exhibits84: Data Table on US - Market size and forecast 2022-2027 ($ million) Exhibits85: Chart on US - Year-over-year growth 2022-2027 (%) Exhibits86: Data Table on US - Year-over-year growth 2022-2027 (%) Exhibits87: Chart on Canada - Market size and forecast 2022-2027 ($ million) Exhibits88: Data Table on Canada - Market size and forecast 2022-2027 ($ million) Exhibits89: Chart on Canada - Year-over-year growth 2022-2027 (%) Exhibits90: Data Table on Canada - Year-over-year growth 2022-2027 (%) Exhibits91: Chart on UK - Market size and forecast 2022-2027 ($ million) Exhibits92: Data Table on UK - Market size and forecast 2022-2027 ($ million) Exhibits93: Chart on UK - Year-over-year growth 2022-2027 (%) Exhibits94: Data Table on UK - Year-over-year growth 2022-2027 (%) Exhibits95: Chart on Germany - Market size and forecast 2022-2027 ($ million) Exhibits96: Data Table on Germany - Market size and forecast 2022-2027 ($ million) Exhibits97: Chart on Germany - Year-over-year growth 2022-2027 (%) Exhibits98: Data Table on Germany - Year-over-year growth 2022-2027 (%) Exhibits99: Chart on China - Market size and forecast 2022-2027 ($ million) Exhibits100: Data Table on China - Market size and forecast 2022-2027 ($ million) Exhibits101: Chart on China - Year-over-year growth 2022-2027 (%) Exhibits102: Data Table on China - Year-over-year growth 2022-2027 (%) Exhibits103: Market opportunity by geography ($ million) Exhibits104: Data Tables on Market opportunity by geography ($ million) Exhibits105: Impact of drivers and challenges in 2022 and 2027 Exhibits106: Overview on Criticality of inputs and Factors of differentiation Exhibits107: Overview on factors of disruption Exhibits108: Impact of key risks on business Exhibits109: Vendors covered Exhibits110: Matrix on vendor position and classification Exhibits111: Azurity Pharmaceuticals Inc. - Overview Exhibits112: Azurity Pharmaceuticals Inc. - Product / Service Exhibits113: Azurity Pharmaceuticals Inc. - Key offerings Exhibits114: Elite Pharmaceuticals Inc. - Overview Exhibits115: Elite Pharmaceuticals Inc. - Business segments Exhibits116: Elite Pharmaceuticals Inc. - Key offerings Exhibits117: Elite Pharmaceuticals Inc. - Segment focus Exhibits118: Hisamitsu Pharmaceutical Co. Inc. - Overview Exhibits119: Hisamitsu Pharmaceutical Co. Inc. - Product / Service Exhibits120: Hisamitsu Pharmaceutical Co. Inc. - Key offerings Exhibits121: Ironshore - Overview Exhibits122: Ironshore - Product / Service Exhibits123: Ironshore - Key offerings Exhibits124: Jazz Pharmaceuticals Plc - Overview Exhibits125: Jazz Pharmaceuticals Plc - Product / Service Exhibits126: Jazz Pharmaceuticals Plc - Key news Exhibits127: Jazz Pharmaceuticals Plc - Key offerings Exhibits128: KemPharm Inc. - Overview Exhibits129: KemPharm Inc. - Product / Service Exhibits130: KemPharm Inc. - Key offerings Exhibits131: Merck and Co. Inc. - Overview Exhibits132: Merck and Co. Inc. - Business segments Exhibits133: Merck and Co. Inc. - Key news Exhibits134: Merck and Co. Inc. - Key offerings Exhibits135: Merck and Co. Inc. - Segment focus Exhibits136: Novartis AG - Overview Exhibits137: Novartis AG - Business segments Exhibits138: Novartis AG - Key offerings Exhibits139: Novartis AG - Segment focus Exhibits140: Pfizer Inc. - Overview Exhibits141: Pfizer Inc. - Product / Service Exhibits142: Pfizer Inc. - Key news Exhibits143: Pfizer Inc. - Key offerings Exhibits144: Purdue Pharma LP - Overview Exhibits145: Purdue Pharma LP - Product / Service Exhibits146: Purdue Pharma LP - Key offerings Exhibits147: Sanofi SA - Overview Exhibits148: Sanofi SA - Business segments Exhibits149: Sanofi SA - Key news Exhibits150: Sanofi SA - Key offerings Exhibits151: Sanofi SA - Segment focus Exhibits152: Takeda Pharmaceutical Co. Ltd. - Overview Exhibits153: Takeda Pharmaceutical Co. Ltd. - Product / Service Exhibits154: Takeda Pharmaceutical Co. Ltd. - Key news Exhibits155: Takeda Pharmaceutical Co. Ltd. - Key offerings Exhibits156: Teva Pharmaceutical Industries Ltd. - Overview Exhibits157: Teva Pharmaceutical Industries Ltd. - Business segments Exhibits158: Teva Pharmaceutical Industries Ltd. - Key news Exhibits159: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibits160: Teva Pharmaceutical Industries Ltd. - Segment focus Exhibits161: Tris Pharma Inc. - Overview Exhibits162: Tris Pharma Inc. - Product / Service Exhibits163: Tris Pharma Inc. - Key offerings Exhibits164: Viatris Inc. - Overview Exhibits165: Viatris Inc. - Business segments Exhibits166: Viatris Inc. - Key offerings Exhibits167: Viatris Inc. - Segment focus Exhibits168: Inclusions checklist Exhibits169: Exclusions checklist Exhibits170: Currency conversion rates for US$ Exhibits171: Research methodology Exhibits172: Validation techniques employed for market sizing Exhibits173: Information sources Exhibits174: List of abbreviations |
| ※참고 정보 중추 신경계 자극제(CNS 자극제)는 중추 신경계의 활동을 증가시키는 약물로, 주로 정신적 또는 신체적 자극을 통한 각성을 유도하는 데 사용됩니다. 이러한 약물은 주로 주의력, 각성 및 반응성을 증가시키기 위해 사용되며, 신경전달물질의 증가 또는 방출을 촉진함으로써 작용합니다. 대표적으로 뇌에서 도파민과 노르에피네프린의 수치를 높이고, 이로 인해 기분이 좋아지고 에너지가 증가하며 집중력이 향상됩니다. CNS 자극제의 종류는 다양합니다. 가장 널리 알려진 것 중 하나는 메틸페니데이트(Methylphenidate)와 암페타민(Amphetamine)입니다. 메틸페니데이트는 주로 주의력 결핍 과잉 행동 장애(ADHD) 치료에 사용되며, 암페타민 계열 약물은 ADHD 치료뿐만 아니라 비만 관리나 기분 장애에도 사용됩니다. 그 외에 코카인 역시 CNS 자극제로 분류되지만, 주로 비의학적 용도로 사용되며 중독성이 강한 약물입니다. CNS 자극제의 주요 용도는 ADHD, 수면 부족, 우울증 및 비만과 관련된 질환의 치료에 있습니다. ADHD 환자에게는 집중력 향상과 행동 조절을 돕기 위해 사용되며, 이로 인해 학업 성취도와 사회적 상호작용에서 긍정적인 효과를 볼 수 있습니다. 또한 이 약물들은 특정 수면 장애나 기면증 치료에도 활용되며, 환자의 낮 시간 동안의 각성을 증진시키는 데 도움을 줍니다. 비만 지치에서도 메틸페니데이트 등의 약물이 사용되며, 이는 식욕 억제 효과가 있기 때문입니다. 하지만 CNS 자극제를 사용할 때는 반드시 전문가의 처방 및 관리가 필요합니다. 이 약물들은 중독성과 의존성의 위험이 있으며, 특히 장기간 사용시 부작용이 발생할 수 있습니다. 일반적인 부작용으로는 불면증, 불안, 고혈압, 두통, 식욕 감소 등이 있으며, 심각한 경우 심장 문제나 정신적 불안정성을 초래할 수 있습니다. 그러므로 이러한 약물을 사용하는 경우 정기적인 의사의 진료와 모니터링이 필요합니다. 최근에는 CNS 자극제의 효과를 극대화 하고 부작용을 최소화하기 위한 다양한 기술 개발이 이루어지고 있습니다. 약물 전달 시스템의 개선, 즉 서방형 제제나 나노기술을 활용한 약물 전달 방식이 개발되면서 약물의 지속 시간이 연장되거나 약물의 효과가 더욱 향상될 수 있는 가능성이 열리고 있습니다. 또한, 약물의 개인 맞춤형 처방이 연구되면서 환자에 따라 적합한 치료 방법을 모색하는 노력도 강해지고 있습니다. 결론적으로, CNS 자극제는 다양한 정신적 및 신체적 상태를 개선하는데 사용되는 중요한 약물이지만, 그 사용의 안전성과 유효성을 확보하기 위해서는 신중한 접근이 필요합니다. 향후 더 나은 치료제를 개발하기 위한 연구와 기술이 지속적으로 필요할 것입니다. |
| ※본 조사보고서 [세계의 중추 신경계 (CNS) 자극제 시장 (2023년~2027년)] (코드 : IRTNTR72695-23) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 중추 신경계 (CNS) 자극제 시장 (2023년~2027년)] 에 대해서 E메일 문의는 여기를 클릭하세요. |

